Similar Stories to Why Shares In Abbvie Soared 18% In September on Bing News

A patent victory and pipeline advances that could lead to billions in additional sales helped catapult AbbVie Inc. (NYSE: ABBV) shares 18% higher in September, according to S&P Global Market Intelligence.On September 7, the U.S. Patent Office refused competitor Coherus's request for an inter partes review of AbbVie's U.S. Patent 9,085,619. The decision added strength to claims by AbbVie's management that it can keep Humira copy-cats out of the market in the U.S.

BING NEWS:
  • AbbVie takes $3.5B hit after emraclidine's phase 2 flop in schizophrenia
    The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma said in a Jan. | The failure of Cerevel's emraclidine in schizophrenia ...
    01/10/2025 - 2:06 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News